

Application No. Not Yet Assigned
Paper Dated: January 12, 2004
In Reply to USPTO Correspondence of N/A
Attorney Docket No. 0470-050079

Customer No. 28289

AMENDMENTS TO THE ABSTRACT

After the claims, please insert a new Abstract Of The Disclosure, which is attached hereto as a separately typed page.

The estrogenic component according to the invention does not have undesirable proliferative effects on breast and/or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and/or climacteric complaints.